Q BIOMED INC.

EDGAR

66 filing records in this dataset, filed from 2014-01-13 to 2023-06-23. Reported financial figures are available; chart coverage varies by period.

Watchlist

Latest quarter

Revenue

26.3 thousand Unit_Standard_USD_Aa7z6sOVEUe_diGdFfCS2Q

2022 Q3 · Unit_Standard_USD_Aa7z6sOVEUe_diGdFfCS2Q

Exact inputs and evidence
  • Revenue: 26271 Unit_Standard_USD_Aa7z6sOVEUe_diGdFfCS2Q Source
Cash and cash equivalents
151 thousand Unit_Standard_USD_fXYgiaGrrEKsGRdvqEBL-A Source
Exact value

151214 Unit_Standard_USD_fXYgiaGrrEKsGRdvqEBL-A

Long-term debt including current maturities
90.1 thousand Unit12 Source
Exact value

90096 Unit12

Shares outstanding
133 million Unit_Standard_shares_smcaEJ1bo0aIiAVmk39CyA Source
Exact value

133027272 Unit_Standard_shares_smcaEJ1bo0aIiAVmk39CyA

Company performance

Up to ten complete financial years · consolidated figures

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2023-06-23.

Financial data available through: 2022-11-30.

Coverage by financial measure
  • Revenue: 2 of 11 periods available· newest 2022-11-30
  • Operating income: 2 of 11 periods available· newest 2022-11-30
  • Net income: 2 of 11 periods available· newest 2022-11-30
  • Operating cash flow: 2 of 11 periods available· newest 2022-11-30
  • capital expenditure: No compatible figures in this window
  • Total assets: Multiple units; comparison withheld· newest 2022-11-30
  • Total liabilities: Multiple units; comparison withheld· newest 2022-11-30
  • Current assets: Multiple units; comparison withheld· newest 2022-11-30
  • Current liabilities: Multiple units; comparison withheld· newest 2022-11-30
  • Cash and cash equivalents: Multiple units; comparison withheld· newest 2020-11-30
  • long term debt: No compatible figures in this window
  • Shares outstanding: Multiple units; comparison withheld· newest 2022-11-30

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

  • Revenue

    +45.4%

    Prior period

    Unit_Standard_USD_-I0FwnEXCECrIwbPJdjWgQ 195,597

    –

    Current period

    Unit_Standard_USD_-I0FwnEXCECrIwbPJdjWgQ 284,352

    –

    Exact inputs and evidence

    284352 − 195597 = 88755 Unit_Standard_USD_-I0FwnEXCECrIwbPJdjWgQ

    195597 Unit_Standard_USD_-I0FwnEXCECrIwbPJdjWgQ · 2020-12-01 – 2021-11-30

    Inspect prior input Prior source

    284352 Unit_Standard_USD_-I0FwnEXCECrIwbPJdjWgQ · 2021-12-01 – 2022-11-30

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

  • Net income

    +Unit_Standard_USD_-I0FwnEXCECrIwbPJdjWgQ 6.19 million

    Prior period

    −Unit_Standard_USD_-I0FwnEXCECrIwbPJdjWgQ 8.24 million

    –

    Current period

    −Unit_Standard_USD_-I0FwnEXCECrIwbPJdjWgQ 2.05 million

    –

    Exact inputs and evidence

    -2052093 − -8240550 = 6188457 Unit_Standard_USD_-I0FwnEXCECrIwbPJdjWgQ

    -8240550 Unit_Standard_USD_-I0FwnEXCECrIwbPJdjWgQ · 2020-12-01 – 2021-11-30

    Inspect prior input Prior source

    -2052093 Unit_Standard_USD_-I0FwnEXCECrIwbPJdjWgQ · 2021-12-01 – 2022-11-30

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

  • Operating cash flow

    +Unit_Standard_USD_-I0FwnEXCECrIwbPJdjWgQ 6.24 million

    Prior period

    −Unit_Standard_USD_-I0FwnEXCECrIwbPJdjWgQ 4.3 million

    –

    Current period

    Unit_Standard_USD_-I0FwnEXCECrIwbPJdjWgQ 1.94 million

    –

    Exact inputs and evidence

    1941404 − -4302036 = 6243440 Unit_Standard_USD_-I0FwnEXCECrIwbPJdjWgQ

    -4302036 Unit_Standard_USD_-I0FwnEXCECrIwbPJdjWgQ · 2020-12-01 – 2021-11-30

    Inspect prior input Prior source

    1941404 Unit_Standard_USD_-I0FwnEXCECrIwbPJdjWgQ · 2021-12-01 – 2022-11-30

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2022 2021-12-01 – 2022-11-30

  • Revenue Unit_Standard_USD_-I0FwnEXCECrIwbPJdjWgQ 284,352 100% of revenue
  • Cost of revenue Unit_Standard_USD_-I0FwnEXCECrIwbPJdjWgQ 293,340 103% of revenue
  • Operating expenses Unit_Standard_USD_-I0FwnEXCECrIwbPJdjWgQ 3.44 million 1,209% of revenue
  • Operating income −Unit_Standard_USD_-I0FwnEXCECrIwbPJdjWgQ 3.45 million −1,212% of revenue
  • Tax, interest and other Derived −Unit_Standard_USD_-I0FwnEXCECrIwbPJdjWgQ 1.39 million −490% of revenue
  • Net income −Unit_Standard_USD_-I0FwnEXCECrIwbPJdjWgQ 2.05 million −722% of revenue

Cash

  • Operating cash flow Unit_Standard_USD_-I0FwnEXCECrIwbPJdjWgQ 1.94 million 683% of revenue
  • Capital expenditure Unavailable An input is unavailable.
  • Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

  • Net income
  • Tax, interest and other
  • Operating costs
  • 2021 Operating loss: operating costs were 3,877% of revenue.
  • 2022 Operating loss: operating costs were 1,312% of revenue.
Values and sources
Revenue breakdown by annual reporting period
PeriodRevenueOperating costsOperating incomeTax, interest and otherNet incomeFree cash flowSource
2021 2020-12-01 – 2021-11-30195597 7584162 Derived -7388565 851985 Derived -8240550 Unavailable
Source
2022 2021-12-01 – 2022-11-30284352 3729968 Derived -3445616 -1393523 Derived -2052093 Unavailable
Source

Amounts are exact, in Unit_Standard_USD_-I0FwnEXCECrIwbPJdjWgQ.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Unit_Standard_USD_-I0FwnEXCECrIwbPJdjWgQ 284.4K 2022
Revenue historyRevenue reported for each complete financial period. Values are shown by financial reporting period. Open Values and sources below for the exact observations and evidence.307.1K230.3K153.6K76.8K0.020212022
Values and sources
Revenue values and source evidence
PeriodSeriesValue(Unit_Standard_USD_-I0FwnEXCECrIwbPJdjWgQ)Source evidence
2021Revenue195597
2022Revenue284352

Revenue growth

Change in revenue from the same financial period one year earlier.

45.4% 2022
Revenue growth historyChange in revenue from the same financial period one year earlier. Values are shown by financial reporting period. Open Values and sources below for the exact observations and evidence.49%37%25%12%0%20212022
Values and sources
Revenue growth values and source evidence
PeriodSeriesValueSource evidence
2021Year over yearNo prior comparable period
2022Year over year45.4%

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -1,211.7% 2022
Net margin -721.7% 2022
Profit margins historyOperating income, net income and free cash flow as a share of revenue. Values are shown by financial reporting period. Open Values and sources below for the exact observations and evidence.337%-885%-2,107%-3,328%-4,550%20212022
  • Operating margin
  • Net margin
  • Free cash flow margin
Values and sources
Profit margins values and source evidence
PeriodSeriesValueSource evidence
2021Operating margin-3,777.4%
2022Operating margin-1,211.7%
2021Net margin-4,213%
2022Net margin-721.7%
2021Free cash flow marginNot reported
2022Free cash flow marginNot reported

Operating cash flow

Cash generated by the company’s normal business operations.

Unit_Standard_USD_-I0FwnEXCECrIwbPJdjWgQ 1.9M 2022
Operating cash flow historyCash generated by the company’s normal business operations. Values are shown by financial reporting period. Open Values and sources below for the exact observations and evidence.2.4M630.3K-1.2M-3.0M-4.8M20212022
Values and sources
Operating cash flow values and source evidence
PeriodSeriesValue(Unit_Standard_USD_-I0FwnEXCECrIwbPJdjWgQ)Source evidence
2021Operating cash flow-4302036
2022Operating cash flow1941404

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.
Values and sources
Free cash flow values and source evidence
PeriodSeriesValue(Unit_Standard_USD_-I0FwnEXCECrIwbPJdjWgQ)Source evidence
2021Free cash flowUnavailable
2022Free cash flowUnavailable

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.
Values and sources
Liabilities to assets values and source evidence
PeriodSeriesValueSource evidence
2021-11-30Liabilities / assetsNot reportedNo source recorded
2022-11-30Liabilities / assetsNot reportedNo source recorded

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.
Values and sources
Current assets to current liabilities values and source evidence
PeriodSeriesValueSource evidence
2021-11-30Current assets / current liabilitiesNot reportedNo source recorded
2022-11-30Current assets / current liabilitiesNot reportedNo source recorded

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
PeriodNet incomeOperating cash flowCapital expenditureFree cash flow
2021 2020-12-01 – 2021-11-30
−Unit_Standard_USD_-I0FwnEXCECrIwbPJdjWgQ 8.24 million
Exact value

Exact value: -8240550 Unit_Standard_USD_-I0FwnEXCECrIwbPJdjWgQ

2020-12-01 – 2021-11-30: -8240550 Unit_Standard_USD_-I0FwnEXCECrIwbPJdjWgQ Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−Unit_Standard_USD_-I0FwnEXCECrIwbPJdjWgQ 4.3 million
Exact value

Exact value: -4302036 Unit_Standard_USD_-I0FwnEXCECrIwbPJdjWgQ

2020-12-01 – 2021-11-30: -4302036 Unit_Standard_USD_-I0FwnEXCECrIwbPJdjWgQ Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

Unavailable Not reported for this period.
Unavailable

Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

2022 2021-12-01 – 2022-11-30
−Unit_Standard_USD_-I0FwnEXCECrIwbPJdjWgQ 2.05 million
Exact value

Exact value: -2052093 Unit_Standard_USD_-I0FwnEXCECrIwbPJdjWgQ

2021-12-01 – 2022-11-30: -2052093 Unit_Standard_USD_-I0FwnEXCECrIwbPJdjWgQ Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

Unit_Standard_USD_-I0FwnEXCECrIwbPJdjWgQ 1.94 million
Exact value

Exact value: 1941404 Unit_Standard_USD_-I0FwnEXCECrIwbPJdjWgQ

2021-12-01 – 2022-11-30: 1941404 Unit_Standard_USD_-I0FwnEXCECrIwbPJdjWgQ Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

Unavailable Not reported for this period.
Unavailable

Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

66 filings · 1,945 latest values · 1,945 originally reported values

Dataset published . Source filing dates and reporting periods are shown separately.

Identifiers: 0001596062, 1596062, QBIO, edgar:1596062, ismo

Also known as ISMO Tech Solutions, Inc., Q BIOMED INC., Q BIOMED INC., Q BioMed Inc.